/Investors

Invus

Crossover fund

New York · Pre-Seed–Late Stage · 8 people tracked

Also known as INVUS FINANCIAL ADVISORS, LLC

Find your way into Invus

488 people in our graph share verified history with the Invus team — schools, employers, funds. One of them is your warm intro.

Ben Savirunlockedknows Leslie Lake · together at RUNI Ventures (overlapped)
knows the team · via FutureFirst
×2knows the team · via International Fund Services (NA) LLC, A State Street Company
×6knows the team · via SS&C GlobeOp
knows the team · via Simmons University
knows the team · via HSBC
✨ Fox Verdict
Sign up to see your fit

Investment thesis

Invus combines the long time horizon and personal attention of a family office with the capabilities of a multi-strategy firm. Anchored by a continuous capital structure funded by Artal since 1985, it invests without predetermined exit timelines, allowing it to support companies from early stages through public-company status. The private equity team makes a handful of transformational investments each year as sole or lead partner, holding minority or majority stakes. The public equity team runs a concentrated long-only portfolio with multi-year holds. Invus Opportunities invests globally in private technology businesses across fintech, marketplaces, healthcare, AI/software, and other tech-enabled sectors. The firm emphasizes alignment, avoiding transaction and monitoring fees.

Source: firm website, verified Sep 22, 2026.

Stage
Pre-Seed–Late Stage
HQ
New York, US
Instruments
Equity
Founded
1985
Last 12 months
11 investments
AUM
$16.5B
Tracked investments
50
Unicorns
3
IPOs
10
Acquisitions
2

Team · 8 people

from the firm's website & public directories
Carmen Tatonin

Member of the Invus Financial Advisors team.

Gretchen Pillerin

Member of the Invus Financial Advisors team.

Lila Brown

Member of the Invus Financial Advisors team.

Rachel Merluzain

Member of the Invus Financial Advisors team.

Nicole Ramroop· Director
Sacha Lainovic· Executive Officer

What they invest in

from 46 of 50 portfolio companies

Biotech ×37Healthtech ×18Medical Devices ×12AI & Machine Learning ×9Deep Tech ×8Digital Health ×6Enterprise Software ×3Advanced Manufacturing ×2

HQs:United States×34France×2United Kingdom×2Japan×1Netherlands×1

Investments · 50 tracked

founders shown can be your intro path

By year:2026 · 102025 · 42024 · 62023 · 22022 · 62021 · 42020 · 32018 · 52016 · 141 dated

Absciabsci.comin𝕏NASDAQ: ABSIJun 2026 · $100M

Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.

AI & Machine LearningBiotechDeep TechPortland, US

Sean McClain(Executive Officer)inPhil Barish(Executive Officer)inZachariah Jonasson(Chief Financial Officer and Chief Business Officer)Shelby Walker(Chief Legal Officer)inRansi Somaratne(Chief Medical Officer)Andreas Busch(Chief Innovation Officer)in

Co-investorsConvergent VenturesDas & Co.IKJ CapitalOregon Venture FundPhoenix Venture PartnersTachyon Ventures+4 more

Agenusagenusbio.comNASDAQ: AGENAug 2026

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in

Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalCommodore CapitalLigand Pharmaceuticals+1 more

Cyclerion Therapeuticscyclerion.comin𝕏NASDAQ: CYCNJul 2023

Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.

BiotechDigital HealthMental HealthCambridge, US

William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)

Co-investorsPappas CapitalAberdare VenturesEcoR1 CapitalPolaris Partners

Gossamer Biogossamerbio.comin𝕏NASDAQ: GOSSJul 2018

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life Sciences+3 more

Kalaris Therapeutics, Inc.kalaristx.comNASDAQ: KLRS

Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion.

BiotechHealthtechBerkeley Heights, US

Srinivas Akkaraju(Director & Co-founder)Mike Dybbs(Director & Co-founder)inNapoleone Ferrara(Director & Co-Founder)Andrew Oxtoby(CEO & Director)inMatthew Feinsod(CMO)Liisa Bayko(CFO)

Co-investorsSamsara BioCapitalRTW Investments L.P.

Neumora Therapeuticsneumoratx.comin𝕏NASDAQ: NMRAOct 2021

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

BiotechDeep TechDigital HealthMedical DevicesWatertown, US

Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)

Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+10 more

Seaport Therapeuticsseaporttx.comin𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)inEric Green(Executive Officer)in

BoardJames I. Healy(Director)

Co-investorsARCH Venture PartnersForesite CapitalHAWKTAILPureTech HealthSofinnova VenturesCPP Investments+3 more

Veradermicsveradermics.cominNYSE: MANE

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Co-investorsLongitude CapitalConnecticut InnovationsLifeSci Venture PartnersOUP (Osage University Partners)SR One Capital Managementabrdn plc

Bullhound Capitalbullhoundcapital.comin✓ verified

Sereact builds AI foundation models that enable industrial robots to perform complex manipulation tasks like warehouse picking and returns handling without retraining.

Advanced ManufacturingAI & Machine LearningDeep TechEnterprise SoftwareQuantum ComputingRoboticsOxford, GB

Ralf Gulde(CEO and co-founder)Marc Tuscher(CTO and co-founder)Gerald Mullally(CEO)

Co-investorsAlpha EdisonBritish Business BankChevron Technology VenturesOxford Science EnterprisesBackstage AB

Leyden Labsleydenlabs.comin✓ verified

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.

BiotechDeep TechHealthtechLeiden, NL

Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)inJintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in

Co-investorsClavystBioF-Prime CapitalGV (Google Ventures)Bluebird VenturesCasdin CapitalEuropean Innovation Council Fund+6 more

Asher Bioasherbio.comin𝕏Mar 2021

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)inYik Andy Yeung(Executive Officer, Director, Promoter)

Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+4 more

Bright Peak Therapeuticsbrightpeaktx.cominJun 2021

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific co-founder; Professor at ETH Zürich)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVersant VenturesVenrockAlexandriaBlackRock+2 more

Cardurioncardurion.cominJul 2024 · $260M

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)inMichael Mendelsohn, M.D.(Founder)in

Co-investorsBain CapitalAscenta CapitalDelos CapitalDigitalis VenturesNew Enterprise Associates (NEA)Bain Capital Life Sciences+4 more

City Therapeuticscitytx.comin𝕏Oct 2024

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)

Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesCasdin CapitalFidelity InvestmentsNYBC Ventures+2 more

Coave Therapeuticscoavetx.comin

Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.

BiotechDeep TechHealthtechMedical DevicesParis, FR

Co-investorsFund+Kurma PartnersSeroba Life SciencesV-Bio VenturesBpifranceNovo Holdings+1 more

Datawordsdatawords.cominJun 2025

Datawords operates a network of production studios across local markets to create and deliver localized content at scale for global brands.

AI & Machine LearningEnterprise SoftwareMarketing TechMedia & EntertainmentSector Agnostic

Co-investorsKeensight Capital

eGenesisegenesis.comFeb 2021

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGeorge M. Church(Director)

Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPKhosla VenturesLifeSci Venture PartnersOUP (Osage University Partners)+12 more

Flareflare.runJul 2026 · $85M

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalNextech Invest+2 more

Flaregetflare.co.ukinJul 2026 · $85M

Flare is a Shopify app that lets merchants set delivery-date rules by postcode, product, and shipping method so customers only see fulfillable dates at checkout, with automation for cut-off times, order tagging, and 3PL syncing.

E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB

Daniel Parekh-Hill(CEO)inAlex Hooper(CTO)in

Co-investorsEntrepreneur FirstAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalNextech Invest+3 more

Flexivflexiv.cominMar 2026

Flexiv builds adaptive robots featuring force control, including the Rizon seven-axis robotic arm and Hesper robot controller.

Advanced ManufacturingAI & Machine LearningDeep TechEnergyHardwareRoboticsSilicon Valley, US

Shiquan Wang(Co-Founder and Chief Executive Officer)inXiyang Yeh(Co-Founder and Chief Technology Officer)in

Co-investorsZhenFundGaorong CapitalGSR VenturesPlug and Play VenturesYF Capital

Generation Biogenerationbio.comFeb 2018 · $100M

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas VentureForesite CapitalCasdin CapitalDeerfield Management CompanyF-Prime CapitalFidelity Investments

Kronos Biokronosbio.cominAug 2020 · $155M

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsEcoR1 CapitalGV (Google Ventures)Nextech InvestVida VenturesBlackRockCommodore Capital+2 more

KSQ Therapeuticsksqtx.comin𝕏Oct 2018 · $80M

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)

BoardALAN L. CRANE(Director)

Co-investorsAlpha Wave GlobalARCH Venture PartnersFlagship PioneeringLAVLG Technology VenturesLilly Asia Ventures+3 more

Kythera Biopharmaceuticalsallergan.comAcquired

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Co-investorsAisling CapitalARCH Venture PartnersProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley Ventures

LifeMine Therapeuticslifeminetx.cominMar 2022

LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.

BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)

Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAisling CapitalAlexandriaBezos Expeditions+7 more

Lycia Therapeuticslyciatx.comin𝕏Jun 2026 · $75M

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in

Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsJanus Henderson Investors+4 more

Metacrinemetacrine.comJun 2018 · $65M

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in

Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more

Miradormiradortech.comFeb 2026 · $250M

Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.

Cloud ComputingEnterprise SoftwareFintechSaaS

Co-investorsNycaNyca PartnersARCH Venture PartnersCore Venture CapitalFidelity InvestmentsOrbiMed+3 more

Mirador Therapeuticsmiradortx.cominJan 2026

Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.

AI & Machine LearningHealthtechMedical DevicesSan Diego, US

Mark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)

BoardPaul Berns(Director)

Co-investorsAquiline Technology GrowthARCH Venture PartnersOrbiMedSanofi VenturesPoint72Venrock Healthcare Capital Partners

MOMA Therapeuticsmomatx.comin𝕏May 2022 · $150M

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsLifeSci Venture PartnersNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion Ventures+3 more

NextPoint Therapeuticsnextpointtx.comin𝕏Feb 2024 · $42.5M

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.

BiotechHealthtechAustin, US

Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)

Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesCatalio Capital ManagementLeaps by BayerSixty Degree Capital

Noema Pharmanoemapharma.cominNov 2025

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+2 more

One Biosciencesonebiosciences.frinJul 2025

OneBio Sciences provides clinical-grade single-cell RNA sequencing analysis of tumor samples to support cancer diagnostics and drug development.

AI & Machine LearningBiotechDigital HealthMedical DevicesParis, FR

Céline Vallot(Co-founder & CSO)in

Co-investorsGalion.exePolytechnique VenturesKima VenturesREDMILESofinnova Partners

Orbital Therapeuticsorbitaltx.comin𝕏Jan 2025Acquired

A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.

BiotechHealthtechMedical Devices

Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalAlexandriaCasdin Capital+2 more

PayJoypayjoy.comin

PayJoy provides financial services and credit access to unbanked and underbanked populations in emerging markets across Africa, Asia, and Latin America.

B2B MarketplacesFintechImpact & Social GoodRetail TechSan Francisco, US

Mark Heynen(Co-Founder & Chief Business Officer)inDoug Ricket(Co-Founder & CEO)inGib Lopez(Co-Founder & COO)inTom Ricket(Co-Founder)inNick Zakrasek(President, Product Development)inAmy Pardee(General Counsel)in

Co-investorsCeniarthCiti VenturesCompoundCore Venture CapitalDnx VenturesEchoVC Partners+18 more

Pretzel Therapeuticspretzeltx.cominSep 2022

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.

BiotechDeep TechHealthtechMedical Devices

Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)

Co-investorsARCH Venture PartnersCambridge Innovation CapitalEIR VenturesAngelini VenturesGV (Google Ventures)HealthCap+1 more

Sensorionsensorion.cominFeb 2024

Sensorion is a French clinical-stage biopharmaceutical company founded in 2009 in Montpellier that develops gene-therapy and small-molecule treatments for inner-ear disorders like genetic deafness and tinnitus.

Co-investorsSofinnova PartnersREDMILESanofi Ventures

Sironaxsironax.comin𝕏Aug 2022 · $200M

Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.

BiotechHealthtechLongevityWaltham, US

Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)

Co-investorsARCH Venture PartnersF-Prime CapitalYuanBio Venture CapitalCBC GroupEight Roads VenturesFuture Innovation+5 more

SQZ Biotechnologiessqzbiotech.cominAug 2018 · $72M

BiotechWatertown, US

Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Armon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)

Co-investors+ND CapitalGV (Google Ventures)Illumina VenturesJDRF T1D FundQuark Venture Inc.Temasek+1 more

Syrossyros.comSep 2022

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+6 more

Trivenitriveni.bioinOct 2024 · $115M

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

Vishal Patelin

Co-investorsAscenta CapitalAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMed+3 more

Unity Biotechnologyunitybiotechnology.cominOct 2016Defunct

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Co-investorsage1ARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla VenturesVenrock+5 more

Whitehawkwhitehawktx.cominMay 2026 · $87.5M

Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development.

BiotechHealthtech

Dave Lennon, PhD(President & CEO)Dave Lennon(President & CEO)in

Co-investorsAvoro Capital Advisors

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Caspian TherapeuticsConvergent TherapeuticsiTeos TherapeuticsLyndraRay TherapeuticsTalaris TherapeuticsVascular Dynamics

Exits · 12

10 IPOs · 2 acquisitions · showing 8

AbsciNASDAQ: ABSIAgenusNASDAQ: AGENCyclerion TherapeuticsNASDAQ: CYCNGossamer BioNASDAQ: GOSSKalaris Therapeutics, Inc.NASDAQ: KLRSNeumora TherapeuticsNASDAQ: NMRASeaport TherapeuticsNASDAQ: SPTXVeradermicsNYSE: MANE

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Invus made?
Invus has 50 tracked investments, 12 of which have exited, including 17 dated in the last 24 months.
What stage does Invus invest at?
Invus invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Invus focus on?
Invus focuses on AI & Machine Learning, Biotech, Consumer, Crypto & Web3, Fintech, FoodTech, Healthtech, Marketplaces, SaaS, Travel & Hospitality.
Where is Invus located?
Invus is headquartered in New York, US.
Who does Invus co-invest with?
Invus most often shares deals with Citi Ventures, Compound, EchoVC Partners, among 22 tracked co-investors.

Similar investors

Featured in lists